Precision BioSciences
104 T.W. Alexander Drive
Building 7
Durham
North Carolina
27713
United States
Tel: 919-314-5512
Fax: 480-393-5553
Website: http://www.precisionbiosciences.com/
57 articles with Precision BioSciences
-
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
9/12/2018
Gilead Sciences and Precision BioSciences announced today that the companies have entered into a strategic collaboration to develop therapies targeting the in vivo elimination of hepatitis B virus (HBV) with Precision’s proprietary genome editing platform, ARCUS.
-
Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.
-
In another example of companies focused on aging-related diseases, Elevian launched with $5.5 million in seed funding. Elevian’s founders came out of Stanford and then Harvard, focused on regenerative effects of “young blood.”
-
Precision Biosciences Announces Collaboration with University of Pennsylvania to Develop Genome Editing Therapeutics
9/4/2018
Precision BioSciences today announced an expansion of their ongoing collaboration with the Gene Therapy Program in the Perelman School of Medicine at the University of Pennsylvania.
-
Precision BioSciences closed on an oversubscribed Series B financing worth $110 million. The funds will be used to continue developing its ARCUS genome editing platform.
-
Precision BioSciences CSO to Join Gene Therapy Session at DIA 2018
6/20/2018
Precision BioSciences CSO Derek Jantz will present and join a panel discussion during the DIA (Drug Information Association) 2018 conference.
-
Precision PlantSciences renamed Elo Life Systems
6/4/2018
Precision BioSciences has announced a new name and brand identity for its food and agriculture business.
-
Precision BioSciences to Present In Vivo Gene Therapy and Ex Vivo Cancer Immunotherapy Data at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
5/14/2018
Precision BioSciences, the ARCUS genome editing company with novel product development programs in gene therapy, cancer immunotherapy and non-GMO food, will give three presentations at the upcoming ASGCT 21st Annual Meeting held in Chicago, Illinois, May 16-19, 2018.
-
ACEA Biosciences Hosted Cancer and Immunotherapy Symposium for Leading Scientists in T Cell Therapy
5/3/2018
ACEA Biosciences, a biotechnology company that develops high performance cell analysis instruments, hosted their 6th annual Cancer Immunotherapy Symposium focused on CAR-T cell and TCR therapy on April 14, 2018 at the W Hotel in Chicago, prior to the 2018 AACR Annual Meeting.
-
David Thomson Joins Precision BioSciences As Chief Development Officer
7/10/2017
-
Precision BioSciences Welcomes Fayaz Khazi, Ph.D. As President Of Plantsciences
6/20/2017
-
Precision BioSciences Release: Company Goes Paperless To Progress Innovation Using IDBS E-Workbook
1/25/2017
-
Baxalta Invests $1.6 Billion to Develop CAR-T Therapies with Precision BioSciences
2/26/2016
-
Precision BioSciences Announces Appointment Of Gene Liau, Ph.D. And Bruce Mccreedy, Ph.D. To Management Team
9/2/2015
-
Precision BioSciences Bags $25.6 Million Series A
5/11/2015
-
Danziger Innovations And Precision BioSciences Announce Successful Genome Modification Collaboration In Ornamental Plants
3/20/2014
-
Precision BioSciences And Agrivida, Inc. Announce Collaborative Trait Development Agreement And Successful Genetic Modification
3/10/2014
-
Precision BioSciences and DuPont Pioneer Announce Publication of Plant Genome Engineering Success
10/31/2013
-
Precision BioSciences Wins Patent Infringement Lawsuit Against Cellectis
5/6/2013
-
Precision BioSciences Announces First Publication of Targeted Knockout Rats Using Engineered Meganuclease Technology
12/11/2012